Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis
Authors' conclusion
The total number of R-TLRs over 10 years after treatment of patients with DES ISR was high. DCBs and particularly DES were able to reduce the need for both first and recurrent revascularization compared with PB treatment.
Study context
- Population
- Patients with drug-eluting stent (DES) in-stent restenosis treated percutaneously
- Participants
- 402 patients500 lesions
- Comparison
- Drug-coated balloon (DCB) or DES vs plain balloon for DES in-stent restenosis (ISR)
- Primary endpoint
- Total repeat target lesion revascularization (R-TLR), first and recurrent events
- Follow-up
- Median 10.3 years
Primary result
As reported in the abstract
Total R-TLR · 10 years
Plain balloon (PB)
162
events
DCB
124
events
DES
87
events
Hazard ratio (95% CI)
DCBvs PBfirst year
0.36(0.24–0.54)
DESvs PBfirst year
0.23(0.14–0.38)
DCBvs PBafter 1 year; nonsignificant
0.77(0.51–1.16)
DESvs PBafter 1 year; significant
0.61(0.39–0.95)
DCBvs DESfirst year; similar
1.54(0.89–2.69)
DCBvs DESafter 1 year; similar
1.26(0.82–1.92)
- Total repeat target lesion revascularization (R-TLRs)
- 373
- Lesions requiring first R-TLR
- 204
Original publication
Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC Cardiovasc Interv. Published 26 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →